VSTM

Verastem, Inc. develops novel therapies for cancers driven by the RAS/MAPK signaling pathway, focusing on rare ovarian cancer and KRAS mutations. The company is advancing small molecule inhibitors, including the first FDA-approved treatment for KRAS-mutant recurrent low-grade serous ovarian cancer. Its pipeline includes therapies targeting KRAS G12D, RAF/MEK, and FAK to address unmet medical needs across various solid tumor types. Verastem operates primarily in the oncology sector, collaborating on clinical trials to enhance its therapeutic offerings.